Active Ingredient(s):Tebentafusp-tebn FDA Approved: * January 25, 2022 Pharm Company: *IMMUNOCORE LTD Category:Cancer
Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer).
The most common side effects include cytokine release syndrome, rash, pyrexia (fever), pruritus (itching), fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting.
Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.&...
* May have multiple approval dates, manufacturers, or labelers.